Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.
Yanhuan FengRongshuang HuangJanet KavanaghLingzhi LiXiaoxi ZengYi LiPing FuPublished in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2019)
Dual inhibition therapy is superior to monotherapy for blood pressure control and urine protein reduction, though such superiority does not translate into improvements in longer-term outcomes, such as reduced progression to ESRD, all-cause mortality, and cardiovascular mortality. An ACEI plus an ARB or a DRI plus an ACEI/ARB may be a safe and effective therapy for patients with DKD, and combination therapy may be suitable for patients with DKD and hypertension and microalbuminuria.
Keyphrases
- combination therapy
- blood pressure
- angiotensin ii
- angiotensin converting enzyme
- hypertensive patients
- type diabetes
- heart rate
- preterm infants
- cardiovascular events
- end stage renal disease
- metabolic syndrome
- amino acid
- protein protein
- wound healing
- gestational age
- chronic kidney disease
- coronary artery disease
- skeletal muscle
- open label
- peritoneal dialysis